India approves QDENGA for dengue prevention in people aged 4–60, making it the country’s first authorised dengue vaccine. The two-dose shot targets all four serotypes and is given three months apart, while rollout, pricing and access details are still awaited. QDENGA Approval Marks a First for India India’s drug regulator has approved Takeda’s QDENGA for preventing dengue in people aged four to 60 years, making it the first dengue
India approves QDENGA for dengue prevention in people aged 4–60, making it the country’s first authorised dengue vaccine. The two-dose shot targets all four serotypes and is given three months apart, while rollout, pricing and access details are still awaited. QDENGA Approval Marks a First for India India’s drug regulator has approved Takeda’s QDENGA for preventing dengue in people aged four to 60 years, making it the first dengue
India is on the verge of introducing its first widely accessible dengue vaccine, marking a critical step in the fight against a disease that continues to spread rapidly across the country. After a key expert panel under the Central Drugs Standard Control Organisation (CDSCO) recommended the importation of Takeda’s tetravalent dengue vaccine, the country could soon see the vaccine rolled out for individuals aged 4 to 60 years. This recommendation comes at a time when dengue cases in India ar
India is on the verge of introducing its first widely accessible dengue vaccine, marking a critical step in the fight against a disease that continues to spread rapidly across the country. After a key expert panel under the Central Drugs Standard Control Organisation (CDSCO) recommended the importation of Takeda’s tetravalent dengue vaccine, the country could soon see the vaccine rolled out for individuals aged 4 to 60 years. This recommendation comes at a time when dengue cases in India ar